N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)

Abstract

Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I), wherein R1 is formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), and R2 is formula (X) or (XI), which are useful for treating, for example, metabolic disorders. Compounds as NLPR3 (pyrin domain-containing protein 3) modulators for the treatment of various conditions, including pulmonary diseases (e.g., type 2 diabetes or obesity), liver diseases (e.g., NAFLD or cirrhosis), pulmonary diseases (e.g., asthma or CORD), central nervous system diseases (e.g., Alzheimer's disease or multiple sclerosis), inflammatory or autoimmune diseases (e.g., rheumatoid arthritis or psoriasis), and cardiovascular diseases (e.g., atherosclerosis or stroke). The present specification discloses the synthesis and characterization of exemplary compounds, as well as their pharmacological data (e.g., pages 67-90, Examples 1-21; Compounds 1-126, Tables). An exemplary compound is, for example, N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-1-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (Example 1; Compound (5)). JPEG2022541254000211.jpg80134

Description

[Technical Field]

[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 62 / 875,402, filed July 17, 2019, which is incorporated herein by reference in its entirety. [Background technology]

[0002] The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, is a crucial component of the innate immune response and inflammatory processes, and its aberrant activity is pathogenic in genetic disorders such as cryopyrin-associated periodic syndromes (CAPS), as well as complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease, and atherosclerosis. Current treatments for NLRP3-associated diseases include biologics targeting IL-1. Small molecule inhibitors of NLRP3 offer an attractive alternative to these biologics, given their potential for improved safety and patient comfort and compliance. Summary of the Invention

[0003] In one aspect, provided herein is a compound of formula (I):

[0004] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony, X1 is O, S, N(R3), or C(NO2)(R4); X2 is -N(R5)- or -C(R5)2-; X3 is -N(R5)- or -C(R5)2-; X4 is -C(O)- or -CH2-; Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is

[0005] [ka] and R2 is

[0006] [ka] and R3 is -OR 14 , -CN, -NO2, or -S(=O)2R 15 and R4 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; each R5 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 heteroalkyl; R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl, or R6 and R7 combined to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is —OH or —O—C1-C6 alkyl, R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13is independently selected from halogen, C-C alkyl, C-C haloalkyl, and C-C heteroalkyl; R 14 is hydrogen or C1-C6 alkyl, R 15 is C1-C6 alkyl, R 16 is hydrogen, C1-C6 alkyl, or —C(O)—C1-C6 alkyl; R 17 is hydrogen or C1-C6 alkyl, R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; and t is 1, 2, or 3.

[0007] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R1 is

[0008] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R6 is -OH. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R1 is

[0009] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, Y is N(R10 In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R 10 is -OH. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, Y is O. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R is

[0010] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, X4 is -C(O)-. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, X4 is -CH2-. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R 17is C1-C6 alkyl. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Y2 is C(R9). In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R9 is hydrogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Y1 is O. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R7 is independently selected from C1-C6 alkyl. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R7 is -CH3. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, p is 1. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, p is 2. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, p is 3. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, p is 0. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, n is 1. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, n is 2. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R1 is

[0011] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R2 is

[0012] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, s is 1. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, t is 1. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R2 is

[0013] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, q is 1. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, q is 0. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, Z is C(R 19 In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R 19 In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R 19 In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R2 is

[0014] [ka] In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, X2 is -N(R5)-. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, X3 is -N(R5)-. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, R5 is hydrogen. In some embodiments of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, X1 is O.

[0015] In another aspect, provided herein is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0016] In some embodiments, provided herein is a method for treating a metabolic disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating a metabolic disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity, and gout.

[0017] In some embodiments, provided herein is a method for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable salt or solvate.In some embodiments, provided herein is a method for treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable salt or solvate, wherein the liver disease is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis and cirrhosis.

[0018] In some embodiments, provided herein is a method for treating a pulmonary disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating a pulmonary disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the pulmonary disease is selected from asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis.

[0019] In some embodiments, provided herein is a method for treating a central nervous system disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating a central nervous system disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the central nervous system disorder is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease.

[0020] In some embodiments, provided herein is a method for treating an autoimmune disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating an autoimmune disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

[0021] In some embodiments, provided herein is a method for treating cardiovascular disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided herein is a method for treating cardiovascular disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein the cardiovascular disease is selected from atherosclerosis or stroke.

[0022] Incorporation by Reference All publications, patents, and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION OF THE INVENTION

[0023] Detailed Description of the Invention definition In the context of this disclosure, a number of terms will be utilized.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood to belong to the claimed subject matter. In the event of multiple definitions for terms herein, the definitions in this section prevail. All patents, patent applications, publications, and publicly available nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referenced herein are incorporated by reference. When referring to a URL or other such identifier or address, it is understood that such identifiers may change and particular information on the Internet may come and go, but that equivalent information may be found by searching the Internet. Reference thereto evidences the availability and public dissemination of such information.

[0025] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claimed subject matter. In this application, the use of the singular includes the plural unless expressly stated otherwise. It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is not limiting.

[0026] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0027] Definitions of standard chemical terms can be found in reference texts including, but not limited to, Carey and Sundberg, "Advanced Organic Chemistry, 4th Ed.", Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology are used.

[0028] Unless specific definitions are provided, the nomenclature used in connection with analytical chemistry, synthetic organic chemistry, and medicinal chemistry, as well as the laboratory procedures and techniques described herein, are those recognized in the art. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery, and patient treatment. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques can be performed, for example, using manufacturer-specific kits or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can generally be performed in a conventional manner and are described in various general and more specific references cited and discussed throughout this specification.

[0029] It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, and compositions described herein.

[0030] As used herein, C1-C x is C1-C2, C1-C3...C1-C x Includes C1-C xrefers to the number of carbon atoms (excluding optional substituents) that make up the moiety it designates.

[0031] An "alkyl" group refers to a straight or branched hydrocarbon chain radical, composed solely of carbon and hydrogen atoms, without any unsaturation. In some embodiments, an "alkyl" group can have 1 to 6 carbon atoms. (Whenever this appears herein, a numerical range, such as "1 to 6," refers to each integer within the given range, e.g., "1 to 6 carbon atoms." This means that the alkyl group may be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 6 carbon atoms, although the current definition also covers occurrences of the term "alkyl" without a specified numerical range.) The alkyl group of the compounds described herein can be designated as "C1-C6 alkyl" or similar designation. By way of example only, "C1-C6 alkyl" indicates that there are 1 to 6 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, and hexyl. The alkyl group can be substituted or unsubstituted. Depending on the structure, an alkyl group can be monoradical or diradical (ie, an alkylene group).

[0032] "Alkoxy" refers to the group "-O-alkyl" where alkyl is as defined herein.

[0033] The term "alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms containing at least one carbon-carbon double bond. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CHCH3, -CH=C(CH3)2, and -C(CH3)=CHCH3. In some embodiments, alkenyl groups can have 2 to 6 carbons. Alkyl groups can be substituted or unsubstituted. Depending on the structure, alkenyl groups can be monovalent or diradical (i.e., alkenylene groups).

[0034] The term "alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms containing at least one carbon-carbon triple bond. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3, and -C≡CCH2CH2CH3. In some embodiments, alkynyl groups can have 2 to 6 carbons. Alkynyl groups can be substituted or unsubstituted. Depending on the structure, alkynyl groups can be monovalent or diradical (i.e., alkynylene groups).

[0035] "Amino" refers to the group -NH2.

[0036] The term "alkylamine" or "alkylamino" refers to an -N(alkyl) x H y "Dialkylamino" refers to the group -N(alkyl)2, where alkyl is as defined herein, and x and y are selected from groups where x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen to which they are attached, can optionally form a cyclic ring system. "Dialkylamino" refers to the group -N(alkyl)2, where alkyl is as defined herein.

[0037] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed from 5, 6, 7, 8, 9, or more than 9 atoms. Aromatic compounds can be optionally substituted. The term "aromatic" includes both aryl groups (e.g., phenyl, naphthalenyl) and heteroaryl groups (e.g., pyridinyl, quinolinyl).

[0038] As used herein, the term "aryl" refers to an aromatic ring in which each of the atoms forming the ring is a carbon atom. The aryl ring can be formed of 5, 6, 7, 8, 9, or more than 9 carbon atoms. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthalenyl. Depending on the structure, the aryl group can be monovalent or diradical (i.e., an arylene group).

[0039] "Carboxy" refers to -COH. In some embodiments, the carboxy moiety can be replaced with a "carboxylic acid bioisostere," which refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties as a carboxylic acid group. A compound having a carboxylic acid moiety can have the carboxylic acid moiety replaced with a carboxylic acid bioisostere and can have similar physical and / or biological properties when compared to the carboxylic acid-containing compound. For example, in one embodiment, the carboxylic acid bioisostere ionizes to approximately the same extent as a carboxylic acid group at physiological pH. Examples of carboxylic acid bioisosteres include, but are not limited to, the following:

[0040] [ka]

[0041] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic group, in which each atom forming the ring (i.e., skeletal atom) is a carbon atom. A cycloalkyl can be saturated or partially unsaturated. A cycloalkyl can be fused to an aromatic ring (in which case the cycloalkyl is attached through a carbon atom of the non-aromatic ring). In some embodiments, cycloalkyl groups include groups having 3 to 10 ring atoms.

[0042] The terms "heteroaryl" or, alternatively, "heteroaromatic" refer to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.

[0043] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group in which at least one skeletal ring atom is a heteroatom selected from nitrogen, oxygen, and sulfur. The radical can be fused with an aryl or heteroaryl. The term heteroalicyclic also includes carbohydrates in all ring forms, including, but not limited to, monosaccharides, disaccharides, and oligosaccharides. Unless otherwise noted, heterocycloalkyls have 2 to 10 carbons in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it is understood that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that comprise the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring).

[0044] The term "halo" or, alternatively, "halogen" means fluoro, chloro, bromo, and iodo.

[0045] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens. The halogens may be the same or different. Non-limiting examples of haloalkyls include -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, and the like.

[0046] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, substituted with one or more fluorine atoms. Non-limiting examples of fluoroalkyl include -CF, -CHF, -CHF, -CHCF, -CFCF, -CFCF, -CF(CH), and the like. Non-limiting examples of fluoroalkoxy groups include -OCF, -OCHF, -OCHF, -OCHCF, -OCFCF, -OCFCF, -OCF(CH), and the like.

[0047] The term "heteroalkyl" refers to an alkyl radical in which one or more skeletal atoms are selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. The heteroatoms can be placed at any interior position of the heteroalkyl radical. Examples include, but are not limited to, -CH2-O-CH3, -CH2-CH2-O-CH3, -CH2-NH-CH3, -CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)-CH3, -CH2-NH-OCH3, -CH2-O-Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Additionally, up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Excluding the number of heteroatoms, a "heteroalkyl" may have from 1 to 6 carbon atoms.

[0048] The term "bond" or "single bond" refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of a larger substructure.

[0049] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is often recognized as a chemical substance embedded in or attached to a molecule.

[0050] As used herein, the substituent "R" appearing by itself without a number designation refers to a substituent selected from among alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heterocycloalkyl.

[0051] "Optional" or "optionally" means that the event or circumstance described below may or may not occur, and the description includes cases where the event or circumstance occurs and cases where it does not occur.

[0052] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional groups individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, C-C alkylalkyne, halo, acyl, acyloxy, -COH, -CO-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and di-substituted amino groups (e.g., -NH, -NHR, -N(R)), and protected derivatives thereof. By way of example, an optional substituent can be L s R s and each L s is independently selected from a bond, -O-, -C(=O)-, -S-, -S(=O)-, -S(=O)2-, -NH-, -NHC(O)-, -C(O)NH-, S(=O)2NH-, -NHS(=O)2, -OC(O)NH-, -NHC(O)O-, -(C1-C6 alkyl)-, or -(C2-C6 alkenyl)-; sare independently selected from H, (C-C alkyl), (C-C cycloalkyl), aryl, heteroaryl, heterocycloalkyl, and C-C heteroalkyl. Protecting groups that may form the protective derivatives of the above substituents can be found in sources such as Greene and Wuts, above.

[0053] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0054] As used herein, the term "therapeutically effective amount" refers to an amount of an NLRP3 inhibitor that, when administered to a mammal in need thereof, is effective to at least partially ameliorate or at least partially prevent a condition associated with skin aging.

[0055] As used herein, the term "expression" includes the process by which a polynucleotide is transcribed into mRNA and translated into a peptide, polypeptide, or protein.

[0056] The term "modulate" encompasses either a decrease or an increase in activity or expression, depending on the target molecule.

[0057] The term "activator" is used herein to refer to any molecular species that, when locally administered, results in activation of the indicated receptor, regardless of whether the molecular species itself binds to the receptor or a metabolite of that molecular species binds to the receptor. Thus, an activator can be a ligand for the receptor, or it can be an activator that is metabolized to a ligand for the receptor, i.e., a metabolite formed in the tissue that is the actual ligand.

[0058] The term "patient" or "mammal" refers to a human, non-human primate, canine, feline, bovine, ovine, porcine, murine, or other veterinary or laboratory mammal. Those skilled in the art will recognize that a treatment that reduces the severity of a condition in one species of mammal is predictive of the effectiveness of that treatment in another species of mammal.

[0059] "Pharmaceutically acceptable salts" includes both acid and base addition salts, and is intended to encompass any and all pharmaceutically suitable salt forms of any one of the compounds described herein. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0060] "Pharmaceutically acceptable acid addition salt" refers to salts which retain the biological effectiveness and properties of the free base and which are not biologically or otherwise undesirable, such as salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphoric acid, etc. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like, such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Salts of amino acids such as arginate, gluconate, and galacturonate are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.

[0061] "Pharmaceutically acceptable base addition salts" refer to salts that retain the biological effectiveness and properties of the free acids and are not biologically or otherwise undesirable. These salts are prepared from the addition of inorganic or organic bases to the free acids. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2 dimethylaminoethanol, 2 diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.

[0062] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably herein. These terms refer to an approach to obtaining beneficial or desired results, including, but not limited to, therapeutic benefit and / or preventative benefit. "Therapeutic benefit" refers to the eradication or amelioration of the underlying disease being treated. Therapeutic benefit is also achieved by the eradication or amelioration of one or more physiological symptoms associated with the underlying disease, such that improvement is observed in the patient even though the patient still suffers from the underlying disease. For preventative benefit, the composition is administered to a patient at risk of developing a particular disease or who reports one or more physiological symptoms of the disease, even if the patient has not been diagnosed with the disease.

[0063] NLRP3 modulators NLRP3 is an intracellular signaling molecule that senses environmental and host-derived factors from many pathogens. Upon activation, NLRP3 binds to the apoptosis-associated speck-like protein, which contains a caspase activation and recruitment domain (ASC). ASC then polymerizes to form large aggregates called ASC specks.

[0064] Polymerized ASC associates with the cysteine protease caspase-1 to form a complex called the inflammasome. This activates active caspase-1, which cleaves the precursor forms of the proinflammatory cytokines IL-1β and IL-18 (pro-IL-γ and pro-IL-18, respectively), thereby activating these cytokines. Caspase-1 also mediates a form of inflammatory cell death known as pyroptosis. ASC speck aggregates can also recruit and activate caspase-8, which processes pro-IL-1β and IL-18, triggering apoptotic cell death.

[0065] Caspase-1 cleaves pro-IL-1β and pro-IL-18 into their active forms, which are secreted from cells. Active caspase-1 also cleaves gasdermin-D, causing pyroptosis. Caspase-1 also mediates the release of alarmin molecules such as IL-33 and high-mobility group box 1 protein (HMGB1) through the control of the pyroptosis cell death pathway. Caspase-1 also cleaves intracellular IL-1R2, resulting in its degradation and allowing the release of IL-1α. In human cells, caspase-1 may also regulate the processing and secretion of IL-37. Many other caspase-I substrates, such as components of the cytoskeleton and glycolytic pathways, may contribute to caspase-I-dependent inflammation.

[0066] NLRP3-dependent ASC specks are released into the extracellular environment where they can activate caspase-1, induce the processing of caspase-1 substrates, and propagate inflammation. Active cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape immune responses to infection and injury. For example, IL-1β signaling induces the secretion of the proinflammatory cytokines IL-6 and TNF. IL-1β and IL-18 synergize with IL-23 to induce IL-17 production by memory CD4 Th17 cells and γδ T cells in the absence of T cell receptor engagement. IL-18 and IL-12 also synergize to induce IFN-γ production from memory T cells and NK cells, driving Th1 responses.

[0067] The inherited CAPS disorders Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and neonatal-onset multisystem inflammatory disease (NOMID) are caused by gain-of-function mutations in NLRP3, thus defining it as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of many complex diseases, including metabolic disorders such as type 2 diabetes, atherosclerosis, obesity, and gout, among others.

[0068] The role of NLRP3 in diseases of the central nervous system is becoming clear, and lung diseases have also been shown to be affected by NLRP3. Furthermore, NLRP3 plays a role in the development of liver disease, kidney disease, and aging. Many of these associations were defined using NLRP3 KO mice, but there are also insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes (T2D), deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1β signaling, leading to cell death and inflammation.

[0069] Current treatments for NLRP3-related diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist anakinra, the neutralizing IL-1β antibody canakinumab, and the soluble decoy IL-1 receptor rilonacept. These approaches have proven successful in treating CAPS, and these biologic agents have been used in clinical trials for other IL-1β-related diseases. Small molecule inhibitors of NLRP3 offer an attractive alternative to these biologics, given their potential for improved safety (minimal risk of infection compared to biologics and ease of withdrawal) and patient comfort and compliance.

[0070] The compounds of formula (I), (Ia) or (Ib) described herein are NLRP3 modulators.The compounds of formula (I), (Ia) or (Ib) described herein and compositions comprising these compounds are useful for treating NLRP3-related diseases, including but not limited to type 2 diabetes, atherosclerosis, obesity and gout.

[0071] In some embodiments, provided herein is a compound of formula (I):

[0072] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony, X1 is O, S, N(R3), or C(NO2)(R4); X2 is -N(R5)- or -C(R5)2-; X3 is -N(R5)- or -C(R5)2-; X4 is -C(O)- or -CH2-; Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is

[0073] [ka] and R2 is

[0074] [ka] and R3 is -OR 14 , -CN, -NO2, or -S(=O)2R 15 and R4 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; each R5 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 heteroalkyl; R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl, or R6 and R7 combine to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is —OH or —O—C1-C6 alkyl, R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C-C alkyl, C-C haloalkyl, and C-C heteroalkyl; R 14 is hydrogen or C1-C6 alkyl, R 15 is C1-C6 alkyl, R 16 is hydrogen, C1-C6 alkyl, or —C(O)—C1-C6 alkyl; R 17 is hydrogen or C1-C6 alkyl, R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; and t is 1, 2, or 3.

[0075] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0076] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0077] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0078] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0079] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0080] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0081] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0082] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0083] [ka] Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0084] [ka] is.

[0085] Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -OH. Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ). Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16 is C1-C6 alkyl. Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is —C(O)—C1-C6 alkyl.

[0086] In some embodiments, in a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R is C-C alkyl, —C-C alkyl-COR 18, C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, —C1-C6 alkyl-CO2R 18 and C1-C6 haloalkyl. Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl. Some embodiments are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is -CH3.

[0087] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5- or 6-membered heteroaryl ring. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5-membered heteroaryl ring selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 6-membered heteroaryl ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

[0088] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 0. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 1. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 2. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 3. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein p is 4.

[0089] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0090] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is —O—C1-C6 alkyl.

[0091] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)-. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)- and R 17 In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is —C(O)— and R 17 is C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2-. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2- and R 17 In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X is —CH— and R 17 is C1-C6 alkyl.

[0092] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is S. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R). In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R) and R is hydrogen or C-C alkyl.

[0093] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein Y is N. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein Y is C(R). In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein Y is C(R) and R is selected from hydrogen and C-C alkyl. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein Y is C(R) and R is hydrogen. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein Y is C(R) and R is C-C alkyl.

[0094] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0095] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0096] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0097] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0098] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0099] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0100] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0101] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0102] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0103] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0104] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0105] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0106] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0107] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0108] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0109] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0110] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0111] [ka] In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0112] [ka] is.

[0113] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0114] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0115] [ka] where s is 1 and t is 1.

[0116] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0117] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0118] [ka] and q is 0. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0119] [ka] and each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0120] [ka] , q is 1, and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is N. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19is F. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0121] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0122] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0123] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0124] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0125] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0126] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0127] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0128] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0129] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0130] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0131] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0132] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0133] [ka] In some embodiments, provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0134] [ka] is.

[0135] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X2 is -N(R5)-. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X2 is -N(R5)- and R5 is hydrogen. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X2 is -N(R5)- and R5 is C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X2 is -C(R5)2-. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X2 is -C(R5)2- and each R5 is hydrogen.

[0136] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is -N(R)-. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is -N(R)- and R is hydrogen. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is -N(R)- and R is C-C alkyl. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is -C(R)-. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is -C(R)- and each R is hydrogen.

[0137] In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is O. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is S. In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is N(R). In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is C(NO)(R). In some embodiments, provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein X is O, S, N(R), or C(NO)(R).

[0138] In some embodiments, provided herein are compounds of formula (Ia);

[0139] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony, X4 is -C(O)- or -CH2-; Y1 is O, S, or N(R8); Y2 is N or C(R9); Y3 is O or N(R 10 ) and Z is N or C(R 19 ) and R1 is

[0140] [ka] and R2 is

[0141] [ka] and R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl; or R6 and R7 combined to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is —OH or —O—C1-C6 alkyl, R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C-C alkyl, C-C haloalkyl, and C-C heteroalkyl; R 16 is hydrogen, C1-C6 alkyl, or —C(O)—C1-C6 alkyl; R 17 is hydrogen or C1-C6 alkyl, R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3, and t is 1, 2, or 3,

[0142] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0143] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0144] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0145] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0146] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0147] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0148] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0149] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0150] [ka] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0151] [ka] is.

[0152] Some embodiments are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -OH. Some embodiments are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ). Some embodiments are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16is C1-C6 alkyl. Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R16) and R 16 is —C(O)—C1-C6 alkyl.

[0153] Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein each R is C-C alkyl, -C-C alkyl-COR 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, —C1-C6 alkyl-CO2R 18 and C1-C6 haloalkyl. Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl. Some embodiments are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is -CH3.

[0154] In some embodiments, provided herein are compounds of Formula (Ia), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5- or 6-membered heteroaryl ring. In some embodiments, provided herein are compounds of Formula (Ia), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5-membered heteroaryl ring selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, provided herein are compounds of Formula (Ia), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 6-membered heteroaryl ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

[0155] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 2. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 3. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 4.

[0156] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0157] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is —O—C1-C6 alkyl.

[0158] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)-. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)- and R 17In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is —C(O)— and R 17 is C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2-. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2- and R 17 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein X is —CH— and R 17 is C1-C6 alkyl.

[0159] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is S. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R). In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R) and R is hydrogen or C-C alkyl.

[0160] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y2 is N. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y2 is C(R9). In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y2 is C(R9) and R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Y2 is C(R9) and R 9 is hydrogen. In some embodiments, provided herein are compounds of Formula (Ia), or pharmaceutically acceptable salts or solvates thereof, wherein Y is C(R), and R is C-C alkyl.

[0161] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0162] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0163] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0164] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0165] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0166] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0167] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0168] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0169] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0170] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0171] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0172] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0173] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0174] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0175] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0176] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0177] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0178] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0179] [ka] is.

[0180] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0181] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0182] [ka] where s is 1 and t is 1.

[0183] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0184] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0185] [ka] and q is 0. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0186] [ka] and each R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0187] [ka] , q is 1, and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is N. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is F. In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0188] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0189] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0190] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0191] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0192] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0193] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0194] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0195] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0196] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0197] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0198] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0199] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0200] [ka] In some embodiments, provided herein are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0201] [ka] is.

[0202] In some embodiments, provided herein is a compound of formula (Ib):

[0203] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony, X4 is -C(O)- or -CH2-; Y1 is O, Y2 is C(R9), Y3 is O or N(R 10 ) and Z is N or C(R 19 ), R1 is

[0204] [ka] and R2 is

[0205] [ka] and R6 is -OH, -C1-C6 alkyl-OH, or -NH(R 16 ) and Each R7 is C1-C6 alkyl, -C1-C6 alkyl-CO2R 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl; or R6 and R7 combined to form a 5- or 6-membered heteroaryl ring; R8 is hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl; R9 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; R 10 is —OH or —O—C1-C6 alkyl, R 11 is C1-C6 alkyl, R 12 is C1-C6 alkyl, Each R 13 is independently selected from halogen, C-C alkyl, C-C haloalkyl, and C-C heteroalkyl; R 16 is hydrogen, C1-C6 alkyl, or —C(O)—C1-C6 alkyl; R 17 is hydrogen or C1-C6 alkyl, R 18 is hydrogen or C1-C6 alkyl, R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 heteroalkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; q is 0, 1, or 2; s is 1, 2, or 3; and t is 1, 2, or 3.

[0206] Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is

[0207] [ka] Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0208] [ka] In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0209] [ka] In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0210] [ka] is.

[0211] Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -OH. Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -C1-C6 alkyl-OH. Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ). Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16 is hydrogen. Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is —NH(R 16 ) and R 16 is C1-C6 alkyl. Some embodiments are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R6 is -NH(R 16 ) and R 16 is —C(O)—C1-C6 alkyl.

[0212] Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R is C-C alkyl, —C-C alkyl-COR 18 , C1-C6 haloalkyl, and C1-C6 heteroalkyl. Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl, —C1-C6 alkyl-CO2R 18 and C1-C6 haloalkyl. Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from C1-C6 alkyl. Some embodiments are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R7 is -CH3.

[0213] In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5- or 6-membered heteroaryl ring. In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 5-membered heteroaryl ring selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein R and R combine to form a 6-membered heteroaryl ring selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

[0214] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, 1, 2, or 3. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 2. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 3. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 4.

[0215] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0216] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is O. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N(R 10 ) and R 10 is —O—C1-C6 alkyl.

[0217] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)-. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -C(O)- and R 17In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is —C(O)— and R 17 is C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2-. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X4 is -CH2- and R 17 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is —CH— and R 17 is C1-C6 alkyl.

[0218] In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is selected from hydrogen and C1-C6 alkyl. In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is hydrogen. In some embodiments, provided herein are compounds of Formula (Ib), or pharmaceutically acceptable salts or solvates thereof, wherein Y2 is C(R9) and R9 is C1-C6 alkyl.

[0219] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is

[0220] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0221] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0222] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0223] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0224] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0225] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0226] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0227] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0228] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0229] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0230] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0231] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0232] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0233] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0234] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0235] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0236] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R is:

[0237] [ka] is.

[0238] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0239] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0240] [ka] where s is 1 and t is 1.

[0241] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0242] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is:

[0243] [ka] and q is 0. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0244] [ka] and each R13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0245] [ka] , q is 1, and R 13 is independently selected from halogen, C1-C6 alkyl, and C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is N. Provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 Provided herein are compounds of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is hydrogen, halogen, —CN, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is F. In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is C(R 19 ) and R 19 is C1-C6 haloalkyl.

[0246] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0247] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0248] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0249] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0250] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0251] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0252] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0253] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0254] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0255] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0256] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0257] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0258] [ka] In some embodiments, provided herein are compounds of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is

[0259] [ka] is.

[0260] In some embodiments, provided herein is a compound selected from the following, or a pharmaceutically acceptable salt or solvate thereof:

[0261] [ka] JPEG0007723652000155.jpg239163 JPEG0007723652000156.jpg250151 JPEG0007723652000157.jpg79163

[0262] In some embodiments, provided herein is a compound selected from the following, or a pharmaceutically acceptable salt or solvate thereof:

[0263] [ka] JPEG0007723652000159.jpg233170

[0264] Any combination of the above groups for the various variables is contemplated herein. Throughout the specification, groups and substituents may be chosen by one skilled in the art to provide stable moieties and compounds.

[0265] In some embodiments, the therapeutic agent (e.g., a compound of Formula (I), (Ia), or (Ib)) is present in the pharmaceutical composition as a pharmaceutically acceptable salt. In some embodiments, any of the above compounds are suitable for any of the methods or compositions described herein.

[0266] Further forms of the compounds disclosed herein Isomers Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusanmen (Z) isomers, as well as their corresponding mixtures. In some circumstances, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulae described herein. In some circumstances, the compounds described herein have one or more chiral centers, with each center existing in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, as well as their corresponding mixtures. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomers resulting from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic resolution of a racemic mixture. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. In some embodiments, separable complexes are preferred (e.g., crystalline diastereomeric salts). In some embodiments, diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography or, preferably, by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomer is then recovered along with the resolving agent by any practical means that does not result in racemization.

[0267] labeled compound In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods for treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods for treating diseases by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds due to the fact that one or more atoms are replaced by atoms that are identical to those described herein but have atomic masses or mass numbers that are different from the atomic masses or mass numbers usually found in nature. Examples of isotopes incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, for example, 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, and 36 The compounds described herein, as well as pharmaceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, that contain the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of the present invention. Certain isotopically labeled compounds, e.g., 3 H and 14 Compounds incorporating radioactive isotopes such as C are useful in drug and / or substrate tissue distribution assays. 3 H, and carbon-14, i.e., 14 Isotopes such as C are particularly preferred for their ease of preparation and detectability. Additionally, heavier isotopes such as deuterium, i.e. 2Substitution with H creates certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced required dosage. In some embodiments, the isotopically labeled compound, its pharmaceutically acceptable salt, ester, solvate, hydrate, or derivative is prepared by any suitable method.

[0268] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0269] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.

[0270] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with a number of inorganic or organic bases, as well as inorganic and organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds described herein, or by separately reacting the purified compounds in free form with the appropriate acid or base and isolating the salt thus formed.

[0271] solvate In some embodiments, the compounds described herein exist as solvates. Some embodiments are methods of treating diseases by administering such solvates. Further described herein are methods of treating diseases by administering such solvates as pharmaceutical compositions.

[0272] Solvates contain either stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, are formed during the crystallization process using pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, and alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents, including but not limited to dioxane, tetrahydrofuran, or MeOH. Furthermore, the compounds provided herein exist in both unsolvated and solvated forms. Generally, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0273] Compound synthesis In some embodiments, synthesis of the compounds described herein is achieved using means described in the chemical literature, using methods described herein, or by a combination thereof. Additionally, solvents, temperatures, and other reaction conditions presented herein may be varied.

[0274] In other embodiments, the starting materials and reagents used in the synthesis of the compounds described herein are synthesized or obtained from commercial sources such as, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and AcrosOrganics.

[0275] In further embodiments, the compounds described herein, and other related compounds with different substituents, can be synthesized using techniques and materials described herein, as well as other methods and methods described in, for example, Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4 th Ed., Vols. A and B(Plenum 2000,2001), and Green and Wuts, Protective Groups in Organic Synthesis 3 rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for preparing the compounds disclosed herein can be derived from reactions, which can be modified by using appropriate reagents and conditions to introduce various moieties found in the formulas provided herein. The following synthetic methods can be used as a guide.

[0276] Use of Protecting Groups In the reactions described, it may be necessary to protect reactive functional groups, such as hydroxy, amino, imino, thio, or carboxy groups, that are desired in the final product to avoid their undesired participation in the reaction. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protecting group is removed. Each protecting group is preferably removable by a different means. Protecting groups that are cleaved under completely different reaction conditions meet the requirement of differential removal.

[0277] Protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and t-butyldimethylsilyl are acid labile and can be used to protect carboxy and hydroxy reactive moieties in the presence of Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties can be blocked with base labile groups, such as methyl, ethyl, and acetyl, in the presence of acid labile groups such as t-butyl carbamate, or amines blocked with carbamates, which are both acid and base stable but hydrolytically removable.

[0278] Carboxylic acid and hydroxy reactive moieties can also be blocked with hydrolytically removable protecting groups such as benzyl groups, while amine groups capable of hydrogen bonding with acids can be blocked with base-labile groups such as Fmoc. Carboxylic acid reactive moieties can be protected by conversion to simple ester compounds as exemplified herein, including conversion to alkyl esters, or they can be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups can be blocked with fluoride-labile silyl carbamates.

[0279] Allyl blocking groups are useful in the presence of acid and base protecting groups because the former are stable and can be subsequently removed by metal or pi-acid catalysts. For example, allyl-blocked carboxylic acids can be removed by Pd catalysis in the presence of acid-labile t-butyl carbamate or base-labile acetate amine protecting groups. 0 It can be deprotected by a catalytic reaction. Yet another form of protecting group is a resin to which a compound or intermediate can be attached. As long as the residue is attached to the resin, the functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.

[0280] Typically, blocking / protecting groups are

[0281] [ka] may be selected from:

[0282] Detailed descriptions of other protecting groups and techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosures.

[0283] Treatment and prevention methods Some embodiments are methods of treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating a metabolic disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity, and gout. Some embodiments are methods of treating type 2 diabetes in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating atherosclerosis in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating obesity in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating gout in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof.

[0284] Some embodiments are methods of treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating liver disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the liver disease is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis, and cirrhosis.

[0285] Some embodiments are methods of treating a pulmonary disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the pulmonary disease is selected from asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis.

[0286] Some embodiments are methods of treating a central nervous system disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the central nervous system disease is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease.

[0287] Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory or autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is rheumatoid arthritis. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is multiple sclerosis. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is psoriasis. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is lupus. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is inflammatory bowel disease.Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is Crohn's disease. Some embodiments are methods of treating an inflammatory or autoimmune disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease is ulcerative colitis.

[0288] Some embodiments are methods of treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating cardiovascular disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein the cardiovascular disease is atherosclerosis or stroke. Some embodiments are methods of treating atherosclerosis in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating stroke in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof.

[0289] Pharmaceutical Compositions and Methods of Administration The NLRP3 modulator described herein is administered to the subject in a biologically compatible form suitable for administration to treat or prevent disease, disorder or condition.The administration of the NLRP3 inhibitor described herein can be any pharmacological form that comprises a therapeutically effective amount of the NLRP3 inhibitor alone or in combination with a pharmaceutically acceptable carrier.

[0290] In certain embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on the selected route of administration and standard pharmaceutical practice, for example, as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0291] Thus, provided herein are pharmaceutical compositions comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers. A carrier(s) (or excipient(s)) is acceptable or suitable if it is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., subject) of the composition.

[0292] Some embodiments are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof.

[0293] Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, are pharmaceutical compositions consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are pharmaceutical compositions consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof.

[0294] In certain embodiments, the compounds described herein are substantially pure in that they contain less than about 5%, or less than about 1%, or less than about 0.1% of other small organic molecules, such as contaminating intermediates or by-products, e.g., produced in one or more steps of the synthetic method.

[0295] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.

[0296] Exemplary pharmaceutical compositions are used in solid, semi-solid, or liquid form, containing one or more of the disclosed compounds as an active ingredient in a mixture with an organic or inorganic carrier or excipient suitable for, for example, external, enteral, or parenteral use. In some embodiments, the active ingredient is formulated with a conventional non-toxic pharmaceutically acceptable carrier for, for example, tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active subject compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect on the disease process or condition.

[0297] In some embodiments, the NLRP3 inhibitors described herein are administered to a subject in a biologically compatible form suitable for topical administration to treat or prevent skin diseases, disorders, or conditions. "Biologically compatible form suitable for topical administration" refers to an administered form of the NLRP3 inhibitor in which the therapeutic effects of the inhibitor outweigh the toxic effects. The administration of the NLRP3 inhibitors described herein can be in any pharmacological form containing a therapeutically effective amount of the NLRP3 inhibitor alone or in combination with a pharmaceutically acceptable carrier.

[0298] The topical administration of NLRP3 inhibitors can be presented in the form of aerosol, semi-solid pharmaceutical composition, powder or solution.The term " semi-solid composition " refers to ointment, cream, salve, jelly or other pharmaceutical composition of substantially similar consistency, suitable for application to the skin.Examples of semi-solid compositions are described in Chapter 17 of Theory and Practice of Industrial Pharmacy, Lachman, Lieberman Kanig, published by Lea and Febiger (1970), and Chapter 67 of Remington's Pharmaceutical Sciences, 15th edition (1975), published by Mack Publishing Company.

[0299] Dermal or skin patches are another method for transdermal delivery of the therapeutic or pharmaceutical compositions described herein. Patches can be provided with absorption enhancers, such as DMSO, to enhance compound absorption. Patches can include patches that control the rate of drug delivery to the skin. Patches can offer a variety of administration systems, including reservoir systems or monolithic systems. Reservoir designs can have four layers: an adhesive layer that directly contacts the skin, a control membrane that controls the diffusion of drug molecules, a reservoir of drug molecules, and a waterproof backing. Such designs deliver a uniform amount of drug over a specified period of time, and the delivery rate must be lower than the saturation limit of different types of skin. For example, monolithic designs typically have only three layers: an adhesive layer, a polymer matrix containing the compound, and a waterproof backing. This design delivers a saturating amount of drug to the skin, thereby controlling delivery. As the amount of drug in the patch decreases below the saturation level, the delivery rate slows.

[0300] In one embodiment, the topical composition can take the form of, for example, a hydrogel based on polyacrylic acid or polyacrylamide, as an ointment, for example using polyethylene glycol (PEG) as a carrier, such as the standard ointment DAB 8 (50% PEG 300, 50% PEG 1500), or as an emulsion, in particular as a microemulsion based on water-in-oil or oil-in-water, optionally with the addition of liposomes. Suitable permeation enhancers (entrainers) include sulfoxide derivatives such as dimethyl sulfoxide (DMSO) or decyl methyl sulfoxide (decyl-MSO) and transcutol (diethylene glycol monoethyl ether) or cyclodextrins, as well as pyrrolidones such as 2-pyrrolidone, N-methyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, or biodegradable N-(2-hydroxyethyl)-2-pyrrolidone and their fatty acid esters; urea derivatives such as dodecyl urea, 1,3-didodecyl urea, and 1,3-diphenyl urea; and terpenes such as D-limonene, menthone, α-terpinol, carbol, limonene oxide, or 1,8-cineole.

[0301] Ointments, pastes, creams, and gels can also contain excipients such as starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, and talc, or mixtures thereof. Powders and sprays can also contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for the production of aerosol pharmaceuticals. Generally, such methods involve pressurizing a container of the solution, or providing a means for pressurizing it, usually with an inert carrier gas, and forcing the pressurized gas through a small orifice. Sprays can additionally contain conventional propellants such as chlorofluorohydrocarbons or volatile unsubstituted hydrocarbons such as butane or propane.

[0302] The carrier may also include other pharmaceutically acceptable excipients to modify or maintain the pH, osmolality, viscosity, clarity, color, sterility, stability, dissolution rate, or odor of the formulation. The anti-skin aging composition may also further include antioxidants, sunscreens, natural retinoids (e.g., retinol), and other additives commonly found in skin treatment compositions.

[0303] In some embodiments for preparing solid compositions such as tablets, the primary active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tablet ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a homogeneous mixture of the disclosed compounds or their non-toxic pharmaceutically acceptable salts. When these preformulation compositions are referred to as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.

[0304] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions are mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) crosslinkers, such as cellulose acetate, ... Disintegrating agents such as vidone, croscarmellose sodium, sodium starch glycolate, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retardants such as paraffin; (6) absorption accelerators such as quaternary ammonium compounds; (7) wetting agents such as docusate sodium, cetyl alcohol, and glycerol monostearate; (8) absorbents such as kaolin and bentonite clay; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. For capsules, tablets, and pills, in some embodiments, the compositions contain buffering agents. In some embodiments, solid compositions of a similar type are also used as fillers for soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0305] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents, or dispersants. In some embodiments, molded tablets are made by molding a mixture of the subject composition moistened with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms such as dragees, capsules, pills, and granules are scored or prepared with coatings and shells, such as enteric coatings and other coatings.

[0306] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders.Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the subject composition, in some embodiments, liquid dosage forms include an inert diluent such as water or other solvents, a solubilizer, and an emulsifier such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan, cyclodextrin and mixtures thereof.

[0307] In some embodiments, suspensions comprise, in addition to the subject composition, suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, metahydroxyaluminum, bentonite, agar, and tragacanth, and mixtures thereof.

[0308] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. In some embodiments, sprays further contain conventional propellants such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons such as butane and propane.

[0309] Alternatively, the compositions and compounds disclosed herein may be administered by aerosol. This can be achieved by preparing aqueous aerosols, liposomal preparations, or solid particles containing the compounds. In some embodiments, non-aqueous (e.g., fluorocarbon propellant) suspensions are used. In some embodiments, sonic nebulizers are used to minimize exposure of the agent to shear, which can degrade the compounds contained in the composition. Typically, aqueous aerosols are made by formulating an aqueous solution or suspension of the composition with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary depending on the requirements of the particular composition, but typically include non-ionic surfactants (Tween, Pluronic, or polyethylene glycol), innocuous proteins such as serum albumin, sorbitan esters, amino acids such as oleic acid, lecithin, glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are generally prepared from isotonic solutions.

[0310] Pharmaceutical compositions suitable for parenteral administration include the subject composition in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders to be reconstituted into sterile injectable solutions or dispersions immediately before use, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0311] Examples of suitable aqueous and non-aqueous carriers used in pharmaceutical compositions include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate and cyclodextrin. Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0312] The dosage of a composition comprising at least one compound described herein will vary depending on the patient's (e.g., human) condition, i.e., stage of disease, general health, age, and other factors.

[0313] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose and the appropriate duration and frequency of administration are determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides a sufficient amount of the composition to provide therapeutic and / or preventive benefits (e.g., more frequent complete or partial remission, or longer disease-free and / or overall survival, or improved clinical outcomes such as reduced severity of symptoms). The optimal dose is generally determined using experimental models and / or clinical trials. In some embodiments, the optimal dose depends on the patient's body weight, weight, or blood volume.

[0314] Oral doses typically range from about 1.0 mg to about 1000 mg, 1 to 4 times or more per day.

[0315] Dose administration may be repeated depending on the pharmacokinetic parameters of the dosage form and the route of administration used.

[0316] It is particularly advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as a single dose for a mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the necessary pharmaceutical carrier. The specifications for the dosage unit form are determined by and directly depend on (a) the inherent characteristics of the NLRP3 inhibitor and the specific therapeutic effect to be achieved, and (b) the inherent limitations of the technology for compounding such active compounds to treat sensitivities in individuals. Specific doses can be easily calculated by those skilled in the art, for example, according to the patient's approximate body weight or body surface area, or the volume of body space occupied. Doses are also calculated depending on the specific route of administration selected. Further refinement of the calculations required to determine the appropriate dosage for treatment is routinely performed by those skilled in the art. Such calculations can be performed without undue experimentation by those skilled in the art in light of the NLRP3 inhibitor activity disclosed herein in assay preparations of target cells. The exact dosage is determined in conjunction with standard dose-response studies. It will be understood that the amount of composition actually administered will be determined by the practitioner in light of the relevant circumstances, including the condition or conditions being treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the selected route of administration.

[0317] The toxicity and therapeutic efficacy of such NLRP3 inhibitors are discussed, for example, in LD 50 (lethal dose for 50% of the population) and ED 50 The LD50 can be determined by standard pharmaceutical procedures in cell cultures or experimental animals to determine the dose that is therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects is the therapeutic index, and the LD50 is the dose that is therapeutically effective in 50% of the population. 50 / ED 50This can be expressed as a ratio of NLRP3 inhibitors to NLRP3 inhibitors. NLRP3 inhibitors that exhibit large therapeutic indices are preferred. While NLRP3 inhibitors that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such inhibitors to the site of affected tissue to minimize potential damage to uninfected cells and thereby reduce side effects.

[0318] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. Such dosages of NLRP3 inhibitors can be administered with little or no toxicity. 50 The circulating concentration of NLRP3 inhibitors is preferably within a range including the IC range. The dosage may vary within this range depending on the dosage form used and the route of administration utilized. For any NLRP3 inhibitor used in the methods described herein, the therapeutically effective dose can be initially estimated from cell culture assays. The IC range determined in cell culture is 50 Doses can be formulated in animal models to achieve a circulating plasma concentration range that includes the NLRP3 inhibitor concentration range (i.e., the concentration of the NLRP3 inhibitor that achieves half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. Plasma levels can be measured, for example, by high-performance liquid chromatography. [Example]

[0319] The following examples are provided for illustrative purposes and are not intended to limit the scope of the claims provided herein. All references cited in these examples and throughout this specification are incorporated herein by reference for all legal purposes provided thereby. The starting materials and reagents used for the synthesis of the compounds described herein can be synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Acros Organics, Fluka, and Fischer Scientific.

[0320] Standard abbreviations and acronyms are used herein as defined in J. Org. Chem. 2007 72(1):23A-24A. Other abbreviations and acronyms are as follows:

[0321] [Table 1]

[0322] Example 1: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (5)

[0323] [ka]

[0324] 1,2,3,5,6,7-Hexahydro-s-indacene-4-amine (2 g, 1.0 equiv.) and trimethylamine (2.26 mL, 1.2 equiv.) were dissolved in dry THF (50 mL). To this solution was added triphosgene (1.14 g, 0.33 equiv.) at 0°C. The resulting mixture was stirred at room temperature for 5 minutes, and then the reaction was heated at 85°C in a sealed tube for 2 hours. The reaction mixture was cooled to room temperature, and the THF was removed in vacuo. The residue was suspended in dry hexane (100 mL) and filtered through a 2-inch pad of silica gel. The filtrate was concentrated in vacuo to give 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1) (1.88 g, 81%) as white crystals.

[0325] A solution of 6,7-dihydrobenzofuran-4(5H)-one (2.0 g, 1.0 equiv.) in methylene chloride (20 mL) was cooled to -10 °C under N2, and chlorosulfonic acid (1.8 g, 1.05 equiv.) was added dropwise over 2 min. The cooling bath was removed, and the reaction was stirred at room temperature under N2 for 3 days. The reaction mixture was cooled to -10 °C, and pyridine (1.3 mL, 1.1 equiv.) was added dropwise. The reaction mixture was stirred at -10 °C for 30 min, and then solid PCl5 (3.4 g, 1.1 equiv.) was added. After stirring at <0 °C for 30 min, the cooling bath was removed, and the reaction was stirred at room temperature overnight. The reaction mixture was cooled to 0 °C and quenched by the addition of ice water. The mixture was stirred for 30 min. The methylene chloride layer was separated, and the aqueous phase was extracted with methylene chloride (20 mL). The combined organic layers were washed with water and dried over sodium sulfate. The solution was evaporated in vacuo to give the sulfonyl chloride 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonyl chloride (2) (2.0 g), which was used directly in the next step.

[0326] To a solution of 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonyl chloride (2) (2.0 g) in THF (15 mL) was added concentrated NHOH (3 mL). The resulting mixture was stirred at room temperature for 3 hours. The reaction was diluted with ethyl acetate (50 mL) and washed with water (2 × 30 mL). The crude mixture was purified by column chromatography to give 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (3) (240 mg).

[0327] To a solution of 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (3) (50 mg, 1.0 equiv.) in THF (2 mL) at 0° C. was added MeMgCl (0.5 mL, 3 M in THF). The resulting mixture was stirred at room temperature for 3 hours. The reaction was quenched with 1N HCl at 0° C. The mixture was extracted with ethyl acetate (2×15 mL), and the combined organic solution was concentrated in vacuo to give 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) (50 mg), which was used directly in the next step.

[0328] To a solution of 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) (50 mg, 1.0 equiv.) in anhydrous THF (4 mL) was added powdered sodium t-butoxide (21 mg, 1.0 equiv.). The mixture was stirred at room temperature for 15 minutes, and then 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (43 mg, 1.0 equiv.) in THF (1 mL) was added dropwise. The resulting mixture was heated at 85 °C for 30 minutes. The mixture was cooled and concentrated in vacuo. The residue was suspended in DCM (50 mL) and washed with 1 N HCl (3 × 20 mL), water, and brine. The solution was concentrated and the residue was purified by HPLC to give N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (5) (28 mg) as a white solid. LCMS: 431.3 (M+H) + .

[0329] Example 2: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (6)

[0330] [ka]

[0331] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (6) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) with 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (3). LCMS: 415.1 (M+H). + .

[0332] Example 3: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (8)

[0333] [ka]

[0334] To a solution of 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (3) (52 mg, 1.0 equiv.) in MeOH (2 mL) at 0 °C was added NaBH (18 mg, 2.0 equiv.). The resulting mixture was stirred at 0 °C for 1 h. The reaction was quenched with 1 N HCl at 0 °C, and the mixture was extracted with ethyl acetate (2 × 15 mL). The crude mixture was purified by column chromatography to give 4-hydroxy-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (7) (42 mg).

[0335] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (8) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) with 4-hydroxy-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (7). LCMS: 417.2 (M+H). + .

[0336] Example 4 Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,5,5-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (11) and N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,7,7-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (12)

[0337] [ka]

[0338] To a solution of sodium bicarbonate (7.2 g, 1.2 equiv.) and chloroacetaldehyde (11.2 g, 1.0 equiv. of a 50 wt.% solution in water) in water (100 mL) at 0 °C, a solution of 4,4-dimethylcyclohexane-1,3-dione (10 g, 1.0 equiv.) in THF (15 mL) was added dropwise over 40 min. The resulting mixture was stirred at room temperature for 18 h, and ethyl acetate (100 mL) was added. The pH was adjusted to pH 1 with 50% H2SO4, and the mixture was stirred vigorously for 3 h. The organic layer was collected, and the acidic layer was extracted with ethyl acetate (3 × 40 mL). The combined organic extracts were washed with water, saturated NaHCO3, brine, and dried over Na2SO4. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give 5,5-dimethyl-6,7-dihydrobenzofuran-4(5H)-one (9) (1.2 g, 10%) and 7,7-dimethyl-6,7-dihydrobenzofuran-4(5H)-one (10) (4.5 g, 38%).

[0339] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,5,5-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (11) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 5,5-dimethyl-6,7-dihydrobenzofuran-4(5H)-one (9). LCMS: 459.2 (M+H). + .

[0340] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,5,5-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (12) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 7,7-dimethyl-6,7-dihydrobenzofuran-4(5H)-one (10). LCMS: 481.0 (M+Na). + .

[0341] Example 5: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (13)

[0342] [ka]

[0343] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,5-dimethyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (13) was prepared in a similar manner as described in Examples 1 and 2. LCMS: 443.1 (M+H) + .

[0344] Example 6: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,5-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (14)

[0345] [ka]

[0346] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,5-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (14) was prepared in a similar manner as described in Examples 1 and 3. LCMS: 445.0 (M+H) + .

[0347] Example 7: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,6-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (16)

[0348] [ka]

[0349] 6-Methyl-6,7-dihydrobenzofuran-4(5H)-one (15) was prepared in a similar manner as described in Example 4 by replacing 4,4-dimethylcyclohexane-1,3-dione with 5-methylcyclohexane-1,3-dione.

[0350] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,6-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (16) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 6-methyl-6,7-dihydrobenzofuran-4(5H)-one (15). LCMS: 445.2 (M+H). + .

[0351] Example 8: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (17)

[0352] [ka]

[0353] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (17) was prepared in a similar manner as described in Examples 1 and 2. LCMS: 429.0 (M+H) + .

[0354] Example 9: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (18)

[0355] [ka]

[0356] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (18) was prepared in a similar manner as described in Examples 1 and 3. LCMS: 431.0 (M+H) + .

[0357] Example 10: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,6,6-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (20)

[0358] [ka]

[0359] 6,6-Dimethyl-6,7-dihydrobenzofuran-4(5H)-one (19) was prepared in a similar manner as described in Example 4 by replacing 4,4-dimethylcyclohexane-1,3-dione with 5,5-dimethylcyclohexane-1,3-dione.

[0360] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4,6,6-trimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (20) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 6,6-dimethyl-6,7-dihydrobenzofuran-4(5H)-one (19). LCMS: 459.2 (M+H). + .

[0361] Example 11: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (21)

[0362] [ka]

[0363] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (21) was prepared in a similar manner as described in Examples 1 and 2. LCMS: 443.1 (M+H) + .

[0364] Example 12: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6,6-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (22)

[0365] [ka]

[0366] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6,6-dimethyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (22) was prepared in a similar manner as described in Examples 1 and 2. LCMS: 445.1 (M+H) + .

[0367] Example 13: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (24)

[0368] [ka]

[0369] 5,6,7,8-Tetrahydro-4H-cyclohepta[b]furan-4-one (23) was prepared in a similar manner as described in Example 4 by replacing 4,4-dimethylcyclohexane-1,3-dione with cycloheptane-1,3-dione.

[0370] N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-4-methyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (24) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-one (23). LCMS: 445.3 (M+H). + .

[0371] Example 14: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (25)

[0372] [ka]

[0373] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (25) was prepared in a similar manner as described in Examples 1 and 3. LCMS: 431.3 (M+H) + .

[0374] Example 15: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-isopropyl-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (27)

[0375] [ka]

[0376] 6-Isopropyl-6,7-dihydrobenzofuran-4(5H)-one (26) was prepared in a similar manner as described in Example 4 by replacing 4,4-dimethylcyclohexane-1,3-dione with 5-isopropylcyclohexane-1,3-dione.

[0377] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-isopropyl-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (27) was prepared in a similar manner as described in Example 1 by replacing 6,7-dihydrobenzofuran-4(5H)-one with 6-isopropyl-6,7-dihydrobenzofuran-4(5H)-one (26). LCMS: 495.1 (M+Na). + .

[0378] Example 16: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-isopropyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (28)

[0379] [ka]

[0380] N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-hydroxy-6-isopropyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (27) was prepared in a similar manner as described in Examples 1 and 3. LCMS: 459.1 (M+H) + .

[0381] Example 17: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,4,5,6-tetrahydrofuro[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (33)

[0382] [ka]

[0383] A solution of 5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-one (22) (2.8 g, 1.0 equiv.) in methylene chloride (10 mL) was cooled to −10 °C under N2, and chlorosulfonic acid (2.2 g, 1.0 equiv.) was added dropwise over 2 min. The reaction was stirred at 0 °C for 5 h and then stirred at room temperature overnight under N2. The reaction was cooled to −10 °C, and pyridine (1.62 g, 1.1 equiv.) was added dropwise. The reaction mixture was stirred at −10 °C for 30 min, and then solid PCl5 (3.88 g, 1.0 equiv.) was added. The resulting reaction was stirred at room temperature overnight. The reaction mixture was cooled to 0 °C and quenched by the addition of ice water. The mixture was stirred for 30 min. The methylene chloride layer was separated, and the aqueous phase was extracted with methylene chloride (2 × 30 mL). The combined organic layer was washed with water and dried over sodium sulfate. The solvent was evaporated in vacuo, and the residue was purified on a silica gel column to give sulfonyl chloride 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonyl chloride (29) (1.2 g, 26%).

[0384] To a solution of 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonyl chloride (29) (600 mg, 1.0 equiv.) in DCM (15 mL) and pyridine (2 mL) was added bis(4-methoxybenzyl)amine (930 mg, 1.5 equiv.). The resulting mixture was stirred at room temperature overnight. The reaction was diluted with DCM (50 mL) and washed with water (2 × 30 mL), 1N HCl, and brine. The crude mixture was purified by column chromatography to give N,N-bis(4-methoxybenzyl)-4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (30) (560 mg, 50%).

[0385] N,N-bis(4-methoxybenzyl)-4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-2-sulfonamide (30) (500 mg) in DMF-DMA (10 mL) was heated at 90 °C for 2 days. Excess DMF-DMA was removed in vacuo, and the residue was dissolved in DCM (5 mL). NHNH (68 mg, 2.0 equiv.) and one drop of acetic acid were then added. The mixture was stirred overnight at room temperature. The reaction was diluted with DCM (20 mL) and washed with saturated NaHCO and brine. The crude mixture was purified on a silica gel column to give N,N-bis(4-methoxybenzyl)-2,4,5,6-tetrahydrofuro[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (31) (401 mg, 76%).

[0386] To a solution of N,N-bis(4-methoxybenzyl)-2,4,5,6-tetrahydrofuro[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (31) (401 mg) in DCM (2 mL) was added TFA (2 mL) and EtSiH (1 mL). The resulting mixture was stirred at room temperature overnight. Additional TFA (1 mL) and EtSiH (0.5 mL) were added, and the reaction was stirred at room temperature for an additional 5 h. The mixture was concentrated in vacuo. The residue was dissolved in DCM (50 mL) and washed with saturated NaHCO and brine. The crude mixture was purified on a silica gel column to give 2,4,5,6-tetrahydrofuro[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (32) (128 mg, 62%).

[0387] To a solution of 2,4,5,6-tetrahydrofuran[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (32) (50 mg, 1.0 equiv.) in anhydrous THF (5 mL) was added powdered sodium t-butoxide (19 mg, 1.0 equiv.). The mixture was stirred at room temperature for 15 minutes, and then 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (40 mg, 1.0 equiv.) in THF (1 mL) was added dropwise. The resulting mixture was stirred at room temperature overnight. The solvent was removed in vacuo. The residue was suspended in ethyl acetate (50 mL) and washed with saturated NaHCO3, water, and brine. The crude mixture was purified on a silica gel column to give N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,4,5,6-tetrahydrofuro[2',3':6,7]cyclohepta[1,2-c]pyrazole-8-sulfonamide (33) (15 mg) as a white solid. LCMS: 453.4 (M+H) + .

[0388] Example 18 Synthesis of (E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(hydroxyimino)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (35) and (Z)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(hydroxyimino)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (36)

[0389] [ka]

[0390] A solution of 4-oxo-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (3) (1.0 equiv.), hydroxylamine (1.5 equiv.), and acetic acid (0.1 equiv.) in EtOH (2 mL) was heated at 80° C. The resulting mixture was cooled and concentrated to give 4-(hydroxyimino)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (34).

[0391] N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (35) and N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (36) were prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) with 4-(hydroxyimino)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (34). For 35 and 36, LCMS: 430.1 (M+H) + .

[0392] Example 19: Synthesis of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (38)

[0393] [ka]

[0394] To a solution of 4-(hydroxyimino)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (34) in CHCN was added SOCl. The mixture was heated at 60 °C, cooled to room temperature, and concentrated under reduced pressure to give 4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (37).

[0395] N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (38) was prepared in a similar manner as described in the last step of Example 1 by replacing 4-hydroxy-4-methyl-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide (4) with 4-oxo-5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-2-sulfonamide (37). LCMS: 430.1 (M+H). + .

[0396] Compounds 39-76 were prepared by procedures similar to those described in the previous examples.

[0397] [Table 2] JPEG0007723652000182.jpg232170 JPEG0007723652000183.jpg243170 JPEG0007723652000184.jpg244170 JPEG0007723652000185.jpg239170 JPEG0007723652000186.jpg252170 JPEG0007723652000187.jpg250170 JPEG0007723652000188.jpg248170 JPEG0007723652000189.jpg245170 JPEG0007723652000190.jpg252170

[0398] Example 20: Mouse BMDMIL-1b assay Mouse bone marrow cells from C57BL6 tibias and femurs were cultured in complete Isocove's medium supplemented with 20 ng / mL MCFS (BMDM medium) at a density of 50 million cells / 15 cm Petri dish. Fresh medium was replaced every 3 days, and bone marrow-derived macrophages were collected, washed, and counted on day 7. Cells were plated at 5 x 10 per well in 100 µL of BMDM medium. 4 Cells were seeded into 96-well plates at a density of 1000 μg / mL and cultured overnight. Cells were stimulated with 200 ng / mL Ultrapure LPS-B5 at 37°C for 3 hours before the addition of pre-diluted compounds. 30 minutes after compound addition, 5 mM ATP was added for a 45-minute secondary stimulation. After stimulation, plates were briefly spun down, and 50 μL of supernatant was collected from each well. ELISA for mouse IL-1b was performed using a pre-coated kit with supernatant diluted 1:10 and 1:100. IL-1b concentrations were calculated based on pre-titrated standards, and compound inhibitory IC50s were generated using the Levenberg-Marquardt attenuated least-squares method.

[0399] [Table 3] JPEG0007723652000192.jpg94167

[0400] Example 21: Human Monocyte IL-1b Assay Human PBMCs were collected from fresh donor blood using a Ficoll gradient. 50 million PBMC cells in 10 mL RPMI were plated into a 15 cm non-tissue culture treated Petri dish and incubated at 37°C for 1 hour. At the end of the incubation period, the medium was gently rocked to remove non-adherent cells. Adherent cells were harvested by gentle scraping and counted. Enriched adherent cells were collected at 2 × 10 per well. 4Cells were plated in 96-well plates and stimulated with 200 ng / mL Ultrapure LPS-B5 for 3 hours before the addition of prediluted compounds. 30 minutes after compound addition, 5 mM ATP was added for a 45-minute secondary stimulation. After stimulation, plates were briefly spun down, and 50 μL of supernatant was collected from each well. ELISA for human IL-1b was performed with 1:10 and 1:100 diluted supernatants using a precoated kit. IL-1b concentrations were calculated based on pre-titrated standards, and compound inhibitory IC50s were generated using the Levenberg-Marquardt attenuated least-squares method.

[0401] The examples and embodiments described herein are for illustrative purposes only, and in some embodiments, various modifications or variations should be included within the scope of the disclosure and the appended claims.

Claims

1. Formula (I): 【Chemical 1】 or a pharmaceutically acceptable salt or solvate thereof, During the ceremony, X １ is O, X ２ HA-N(R ５ ) - and X ３ HA-N(R ５ ) - and Y １ is O, Y ２ is C(R ９ ) and Y ３ is O or N(R １０ ) and Z is C(R １９ ) and R １ teeth, 【Chemistry 2】 and R ２ teeth 【Chemistry 3】 and Each R ５ are independently selected from hydrogen, R ６ is —OH, Each R ７ is C １ -C ６ independently selected from alkyl, R ９ is hydrogen, R １０ is —OH or —O—C １ -C ６ is alkyl, R １１ is C １ -C ６ is alkyl, R １２ is C １ -C ６ is alkyl, Each R １３ is a halogen, C １ -C ６ Alkyl, and C １ -C ６ haloalkyl; R １９ is hydrogen, halogen, -CN, C １ -C ６ Alkyl, or C １ -C ６ is haloalkyl, n is 1 or 2, p is 0, 1, 2, or 3; q is 0 or 1; s is 1, and t is 1, A compound or a pharmaceutically acceptable salt or solvate thereof.

2. R １ but 【Chemistry 4】 2. The compound of claim 1, wherein:

3. R １ but 【Chemistry 5】 and Y ３ is N (R １０ ) and R １０ The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein is -OH.

4. Each R ７ Ga-CH ３ 2. The compound of claim 1, wherein:

5. 2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1.

6. R １ but, 【Chemistry 7】 2. The compound of claim 1, wherein:

7. R ２ but 【Chemistry 8】 and R １９ 2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein is hydrogen or halogen.

8. R ２ but 【Chemistry 9】 and each R １３ 10. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein: is independently selected from halogen.

9. q is 0 and R １９ 9. The compound of claim 8, or a pharmaceutically acceptable salt or solvate thereof, wherein is hydrogen or halogen.

10. R ２ but, 【Chemistry 10】 2. The compound of claim 1, wherein:

11. A compound or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 2. The compound of claim 1 selected from: or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

13. 12. Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a metabolic disease, a liver disease, a pulmonary disease, a central nervous system disease, a cardiovascular disease, or an inflammatory or autoimmune disease in a patient in need thereof.

14. 14. The use of claim 13, wherein the metabolic disease is selected from type 2 diabetes, atherosclerosis, obesity, and gout; the liver disease is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), viral hepatitis, and cirrhosis; the lung disease is selected from asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis; the central nervous system disease is selected from Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson's disease; the cardiovascular disease is atherosclerosis or stroke; and the inflammatory or autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

Images